Abstract
α4 and β2 nicotinic cholinergic receptor (nAChR) subunits can assemble in heterologous expression systems as pentameric receptors with different subunit stoichiometries that exhibit differential sensitivity to activation by acetylcholine, yielding biphasic concentration-effect curves. nAChR-mediated 86Rb+ efflux in mouse brain synaptosomes also displays biphasic acetylcholine (ACh) concentration-response curves. Both phases are mediated primarily by α4β2*-nAChR, because deletion of either the α4 or β2 subunit reduces response at least 90%. A relatively larger decrease in the component of 86Rb+ efflux with lower ACh sensitivity occurred with partial deletion of α4 (α4+/-), whereas a larger decrease in the component with higher ACh sensitivity was elicited by partial deletion of β2 (β2+/-). Immunoprecipitation with selective antibodies demonstrated that more than 70% of [3H]epibatidine binding sites in both regions contained only α4 and β2 subunits. Subsequently, α4 and β2 subunit content in the cortex and thalamus of α4 and β2 wild types and heterozygotes was analyzed with Western blots. Partial deletion of α4 decreased and partial deletion of β2 increased the relative proportion of the α4 subunit in assembled receptors. Although these methods do not allow exact identification of stoichiometry of the subtypes present in wild-type cortex and thalamus, they do demonstrate that cortical and thalamic nAChRs of the α4+/- and β2+/- genotypes differ in relative expression of α4 and β2 subunits a result that corresponds to the relative functional changes observed after partial gene deletion. These results strongly suggest that α4β2-nAChR with different stoichiometry are expressed in native tissue.
Footnotes
-
This work was supported by National Institute on Drug Abuse grant DA003194 and animal resources grant DA015663 (to A.C.C.), Fondazione Cariplo grant 2006/0882/104878 (to F.C.), and Fondazione Cariplo grant 2006/0779/109251 and FP7-Health-2007A grant 202088-NeuroCypres from the European Commission (to C.G.).
-
ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; ACh, acetylcholine; A85380, 3-((2S)-azetidinylmethoxy)pyridine; αBgtx, α-bungarotoxin; PMSF, phenylmethylsulfonyl fluoride; Ab, polyclonal antibody; ANOVA, analysis of variance.
- Received January 11, 2008.
- Accepted March 12, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|